Treatment of convulsive status epilepticus in infants and young children in Japan.

K Sugai
{"title":"Treatment of convulsive status epilepticus in infants and young children in Japan.","authors":"K Sugai","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We review the types and causes of convulsive status epilepticus (CSE) in infants and young children in Japan, and discuss the current recommendations for the use of intravenous (IV) drugs in managing this condition, and report on our clinical experiences. There are prolonged or continuous CSE and clustered or intermittent CSE, and treatments are different between them. In Japan, fosphenytoin and IV preparation of lorazepam and phenobarbital are not available. Recently, midazolam and lidocaine (LDC) have been widely used, although neither of these drugs have official approval for the management of CSE. Febrile seizures and epilepsies are common causes of CSE in infants and young children in Japan, followed by benign infantile convulsions (BIC), convulsions with gastroenteritis (CwG), and acute encephalitis with refractory CSE and intractable epilepsy (AECSEE), which are familiar disorders in Japan. BIC and CwG frequently present with clustered CSE and do not respond to IV diazepam, but have an excellent response with oral carbamazepine or IV LDC. CSE in AECSEE requires control with barbiturate coma. The Research Committee on Clinical Evidence of Medical Treatment for Status Epilepticus in Childhood has developed a proposed guideline for the treatment of CSE in childhood in Japan by an evidence-based approach and consensus conference. Initial management of seizures should be attempted mainly with IV diazepam, the second-line treatment involves IV midazolam followed by IV phenytoin if seizures persist, and the third-line treatment requires barbiturate coma. However, our experience of 247 episodes of CSE in 77 patients, predominantly with chronic epilepsy, required different second-line treatments for prolonged CSE compared with clustered CSE: the former were treated with IV midazolam or pentobarbital, and the latter were given IV phenytoin or LDC. We propose modifications to the guideline for CSE that the second-line treatment is divided by prolonged CSE and clustered CSE, and that the procedures for brain protection and systemic management are added.</p>","PeriodicalId":75395,"journal":{"name":"Acta neurologica Scandinavica. Supplementum","volume":"186 ","pages":"62-70"},"PeriodicalIF":0.0000,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta neurologica Scandinavica. Supplementum","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We review the types and causes of convulsive status epilepticus (CSE) in infants and young children in Japan, and discuss the current recommendations for the use of intravenous (IV) drugs in managing this condition, and report on our clinical experiences. There are prolonged or continuous CSE and clustered or intermittent CSE, and treatments are different between them. In Japan, fosphenytoin and IV preparation of lorazepam and phenobarbital are not available. Recently, midazolam and lidocaine (LDC) have been widely used, although neither of these drugs have official approval for the management of CSE. Febrile seizures and epilepsies are common causes of CSE in infants and young children in Japan, followed by benign infantile convulsions (BIC), convulsions with gastroenteritis (CwG), and acute encephalitis with refractory CSE and intractable epilepsy (AECSEE), which are familiar disorders in Japan. BIC and CwG frequently present with clustered CSE and do not respond to IV diazepam, but have an excellent response with oral carbamazepine or IV LDC. CSE in AECSEE requires control with barbiturate coma. The Research Committee on Clinical Evidence of Medical Treatment for Status Epilepticus in Childhood has developed a proposed guideline for the treatment of CSE in childhood in Japan by an evidence-based approach and consensus conference. Initial management of seizures should be attempted mainly with IV diazepam, the second-line treatment involves IV midazolam followed by IV phenytoin if seizures persist, and the third-line treatment requires barbiturate coma. However, our experience of 247 episodes of CSE in 77 patients, predominantly with chronic epilepsy, required different second-line treatments for prolonged CSE compared with clustered CSE: the former were treated with IV midazolam or pentobarbital, and the latter were given IV phenytoin or LDC. We propose modifications to the guideline for CSE that the second-line treatment is divided by prolonged CSE and clustered CSE, and that the procedures for brain protection and systemic management are added.

日本婴幼儿惊厥癫痫持续状态的治疗。
我们回顾了日本婴幼儿惊厥性癫痫持续状态(CSE)的类型和原因,讨论了目前静脉注射(IV)药物治疗这种疾病的建议,并报告了我们的临床经验。CSE分为延长型或连续型CSE和集群型或间歇型CSE,处理方法不同。在日本,苯妥英和静脉注射的劳拉西泮和苯巴比妥是不可买的。最近,咪达唑仑和利多卡因(LDC)被广泛使用,尽管这两种药物都没有被正式批准用于CSE的治疗。在日本,热性惊厥和癫痫是婴幼儿CSE的常见病因,其次是良性婴儿惊厥(BIC)、惊厥合并胃肠炎(CwG)、急性脑炎合并难治性CSE和顽固性癫痫(AECSEE),这是日本常见的疾病。BIC和CwG经常出现群集性CSE,静脉注射地西泮无反应,但口服卡马西平或静脉注射LDC有很好的反应。AECSEE的CSE需要巴比妥昏迷控制。儿童期癫痫持续状态医学治疗临床证据研究委员会通过循证方法和共识会议制定了日本儿童期CSE治疗的拟议指南。癫痫发作的初始治疗主要是静脉滴注安定,二线治疗包括静脉滴注咪达唑仑,如果癫痫发作持续,再静脉滴注苯妥英,三线治疗需要巴比妥酸钠昏迷。然而,我们对77例247次CSE患者的经验,主要是慢性癫痫,与群集性CSE相比,长期CSE需要不同的二线治疗:前者接受静脉咪达唑仑或戊巴比妥治疗,后者接受静脉苯妥英或LDC治疗。我们建议修改CSE指南,将二线治疗分为延长CSE和集群CSE,并增加脑保护和系统管理程序。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信